DOR BioPharma to Present at the Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference
May 04 2005 - 10:51AM
Business Wire
DOR BioPharma, Inc. (AMEX: DOR) ("DOR" or the "Company"), announced
today that Gregory J. Davenport, Ph.D., President of DOR's
BioDefense Division, will be making a presentation at the Rodman
& Renshaw Techvest 2nd Annual Global Healthcare Conference on
Thursday May 5, 2005. Dr. Davenport will provide a review on recent
progress and anticipated upcoming events relating to DOR's
BioTherapeutic and BioDefense programs. Dr. Davenport's
presentation will take place on Thursday, May 5, 2005, at 11:35 AM
local time at the Intercontinental Hotel in Paris, France. About
DOR BioPharma, Inc. DOR BioPharma, Inc. is a biopharmaceutical
company focused on the development of biomedical countermeasures
and therapeutic products for areas of unmet medical needs. Through
our BioTherapeutics Division, we are developing therapeutic
products that utilize the oral route of delivery. Our lead product,
orBec(R) (oral beclomethasone dipropionate), is a potent,
locally-acting corticosteroid being developed for the treatment of
intestinal Graft-versus-Host disease (iGVHD), a common serious
complication of bone marrow transplantation for cancer, as well as
other gastrointestinal disorders characterized by severe
inflammation. We intend to file a new drug application (NDA) with
the FDA for orBec(R) for the treatment of intestinal iGVHD later
this year. Through our BioDefense Division, we are developing
biomedical countermeasures pursuant to the paradigm established by
the recently enacted Project BioShield Act of 2004. Our biodefense
products in development are bioengineered vaccines designed to
protect against the deadly effects of ricin toxin and botulinum
toxin, both of which are considered serious bioterrorism threats.
Our ricin toxin vaccine, RiVax(TM), is currently the subject of a
Phase I clinical trial in normal volunteers. We have also recently
announced the initiation of a new botulinum toxin therapeutic
development program based on rational drug design. For further
information regarding DOR BioPharma, please visit the Company's
website located at http://www.dorbiopharma.com. This press release
contains forward-looking statements, within the meaning of Section
21E of the Securities Exchange Act of 1934, that reflect DOR
BioPharma's current expectations about its future results,
performance, prospects and opportunities, including statements
regarding the potential use of orBec(R) for the treatment of iGVHD
and the prospects for regulatory filings for orBec(R). Where
possible, DOR BioPharma has tried to identify these forward-looking
statements by using words such as "anticipates", "believes",
"intends", or similar expressions. These statements are subject to
a number of risks, uncertainties and other factors that could cause
actual events or results in future periods to differ materially
from what is expressed in, or implied by, these statements. DOR
BioPharma cannot assure you that it will be able to successfully
develop or commercialize products based on its technology,
including orBec(R), particularly in light of the significant
uncertainty inherent in developing vaccines against bioterror
threats, manufacturing and conducting preclinical and clinical
trials of vaccines, and obtaining regulatory approvals, that its
technologies will prove to be safe and effective (including that
the results of its Phase I clinical trial of RiVax(TM) will
demonstrate acceptable safety and immunogenicity/efficacy), that
its cash expenditures will not exceed projected levels, that it
will be able to obtain future financing or funds when needed, that
product development and commercialization efforts will not be
reduced or discontinued due to difficulties or delays in clinical
trials or due to lack of progress or positive results from research
and development efforts, that it will be able to successfully
obtain any further grants and awards, maintain its existing grants
which are subject to performance, enter into any biodefense
procurement contracts with the U.S. Government or other countries,
that it will be able to patent, register or protect its technology
from challenge and products from competition or maintain or expand
its license agreements with its current licensors, that it will be
able to maintain its listing on the American Stock Exchange, or
that its business strategy will be successful. Important factors
which may affect the future use of orBec(R) for iGVHD include the
risks that: because orBec(R) did not achieve statistical
significance in its primary endpoint in the pivotal Phase III
clinical study (i.e. a p-value of less than or equal to 0.05), the
FDA may not consider orBec(R) approvable based upon existing
studies, orBec(R) may not show therapeutic effect or an acceptable
safety profile in future clinical trials, if required, or could
take a significantly longer time to gain regulatory approval than
DOR BioPharma expects or may never gain approval; Dor BioPharma is
dependent on the expertise, effort, priorities and contractual
obligations of third parties in the clinical trials, manufacturing,
marketing, sales and distribution of its products; or orBec(R) may
not gain market acceptance; and others may develop technologies or
products superior to orBec(R). These and other factors are
described from time to time in filings with the Securities and
Exchange Commission, including, but not limited to, DOR BioPharma's
most recent reports on Form 10-QSB and Form 10-KSB. DOR BioPharma
assumes no obligation to update or revise any forward-looking
statements as a result of new information, future events, and
changes in circumstances or for any other reason.
Dor (AMEX:DOR)
Historical Stock Chart
From Jul 2024 to Aug 2024
Dor (AMEX:DOR)
Historical Stock Chart
From Aug 2023 to Aug 2024